<ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
<p>Centessa Pharmaceuticals PLC 贊助的 ADR (NASDAQ:CNTA - 免費報告) - Lifesci Capital 的分析師在 11 月 13 日星期四發佈的研究報告中上調了對 Centessa Pharmaceuticals 2025 財年的盈利預期。Lifesci Capital 分析師 F. Brisebois 現在預計該公司將發佈每股收益為（$1.37），高於之前的預期（$1.39）。Lifesci Capital 目前對該股票的評級為 “強力買入”。市場普遍預計 Centessa Pharmaceuticals 當前全年的每股收益為（$1.60）。Lifesci Capital 還對 Centessa Pharmaceuticals 2025 年第四季度的每股收益預期為（$0.39），2026 年第一季度的每股收益預期為（$0.39），2026 年第二季度的每股收益預期為（$0.39），2026 年第三季度的每股收益預期為（$0.42），2026 年第四季度的每股收益預期為（$0.42），以及 2026 財年的每股收益預期為（$1.61）。</p>
<p>其他一些股票分析師也對 CNTA 發表了看法。華爾街 Zen 在 10 月 27 日星期一的研究報告中將 Centessa Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。Stephens 在 10 月 28 日星期二的報告中開始覆蓋 Centessa Pharmaceuticals。他們對該股票設定了 “超配” 評級和 $35.00 的目標價。Chardan Capital 在 8 月 12 日星期二的報告中重申了 “買入” 評級，並對 Centessa Pharmaceuticals 的股票設定了 $30.00 的目標價。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了 Centessa Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，Truist Financial 在 11 月 5 日星期三的報告中對 Centessa Pharmaceuticals 股票設定了 $30.00 的目標價。一位股票研究分析師對該股票給予了強力買入評級，十位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 $33.11。</p>
<p><strong>查看我們對 CNTA 的最新分析</strong></p>
<h2>Centessa Pharmaceuticals 價格表現</h2>
<p>CNTA 股票在星期一開盤價為 $27.61。Centessa Pharmaceuticals 的一年最低價為 $9.60，一年最高價為 $27.72。該公司的債務與股本比率為 0.36，流動比率為 10.56，速動比率為 10.57。該公司的市值為 37 億美元，市盈率為 -15.09，貝塔值為 1.56。該公司的 50 日簡單移動平均為 $23.17，200 日簡單移動平均為 $17.56。</p>
<p>Centessa Pharmaceuticals (NASDAQ:CNTA - 獲取免費報告) 最近在 11 月 5 日星期三發佈了季度財報。該公司報告的每股收益為（$0.41），低於分析師的共識預期（$0.39）$0.02。</p>
<h2>Centessa Pharmaceuticals 內部活動</h2>
<p>在相關消息中，內部人士 Mario Alberto Accardi 在 10 月 27 日星期一以每股平均價格 $25.00 出售了 8,000 股該公司的股票，總價值為 $200,000.00。出售後，該內部人士在公司中持有 194,394 股，價值約為 $4,859,850。這筆交易使其持股減少了 3.95%。該交易已在證券交易委員會的備案中披露，可以通過此鏈接訪問。此外，首席技術官 Tia L. Bush 在 11 月 12 日星期三以每股平均價格 $26.00 出售了 40,000 股該公司的股票，總價值為 $1,040,000.00。交易後，首席技術官持有 121,503 股公司股票，價值 $3,159,078。這筆交易代表其持股減少了 24.77%。該銷售的 SEC 備案提供了更多信息。在上個季度，內部人士出售了價值 $4,106,481 的 179,964 股公司股票。內部人士持有公司股票的比例為 7.09%。</p>
<h2>Centessa Pharmaceuticals 的機構交易</h2>
<p>幾家對沖基金最近對 CNTA 的持倉進行了調整。Avoro Capital Advisors LLC 在第三季度將其在 Centessa Pharmaceuticals 的股份增加了 116.2%。Avoro Capital Advisors LLC 現在擁有 10,808,080 股該公司的股票，價值 $262,096,000，此前在此期間又購買了 5,808,080 股。Adage Capital Partners GP L.L.C. 在第一季度將其在 Centessa Pharmaceuticals 的持股增加了 35.8%。Adage Capital Partners GP L.L.C. 現在擁有 6,954,000 股該公司的股票，價值 $99,999,000，此前在上個季度又購買了 1,834,973 股。Federated Hermes Inc. 在第三季度購買了 Centessa Pharmaceuticals 的新頭寸，價值約為 $42,429,000。Balyasny Asset Management L.P. 在第二季度獲得了 Centessa Pharmaceuticals 的新頭寸，價值 $16,052,000。最後，Commodore Capital LP 在第二季度將其在 Centessa Pharmaceuticals 的持倉增加了 39.3%。Commodore Capital LP 現在擁有 3,298,289 股該公司的股票，價值 $43,340,000，此前在此期間又購買了 930,711 股。機構投資者和對沖基金持有公司股票的比例為 82.01%。</p>
<h2>Centessa Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於為患者發現、開發和提供藥物。其產品管線包括 SerpinPC，一種用於治療 A 型和 B 型血友病的活化蛋白 C 抑制劑；以及 ORX750，一種用於治療嗜睡症和其他睡眠障礙的口服 OX2R 激動劑。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Centessa Pharmaceuticals</li>
<li>內部人士出售解釋：它能否影響你的投資選擇？</li>
<li>4 只寒冷天氣股票，適合冬季消費熱潮</li>
<li>深入瞭解買賣差價</li>
<li>迪士尼股票下跌——收益能否為 YouTube TV 和解鋪平道路？</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>Meta 的痛苦可能是你的機會：這是一個罕見的買入窗口嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
<p>在你考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Centessa Pharmaceuticals 並不在名單上。</p>
<p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CNTA

<p>Lifesci Capital 已上調 Centessa Pharmaceuticals 的 2025 財年盈利預期，現在預計每股收益為（$1.37），高於之前的（$1.39）。該公司對該股票維持 “強力買入” 評級。Centessa 的股票共識目標價為 $33.11，平均評級為 “適度買入”。近期的內部交易和機構投資表明市場對該公司的顯著興趣。該股票開盤價為 $27.61，市值為 37 億美元</p>

<ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
</div><p>Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) - Analysts at Lifesci Capital raised their FY2025 earnings estimates for Centessa Pharmaceuticals in a research report issued on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings per share of ($1.37) for the year, up from their previous estimate of ($1.39). Lifesci Capital currently has a &#34;Strong-Buy&#34; rating on the stock. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals' Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals PLC 贊助的 ADR (NASDAQ:CNTA - 免費報告) - Lifesci Capital 的分析師在 11 月 13 日星期四發佈的研究報告中上調了對 Centessa Pharmaceuticals 2025 財年的盈利預期。Lifesci Capital 分析師 F. Brisebois 現在預計該公司將發佈每股收益為（$1.37），高於之前的預期（$1.39）。Lifesci Capital 目前對該股票的評級為 “強力買入”。市場普遍預計 Centessa Pharmaceuticals 當前全年的每股收益為（$1.60）。Lifesci Capital 還對 Centessa Pharmaceuticals 2025 年第四季度的每股收益預期為（$0.39），2026 年第一季度的每股收益預期為（$0.39），2026 年第二季度的每股收益預期為（$0.39），2026 年第三季度的每股收益預期為（$0.42），2026 年第四季度的每股收益預期為（$0.42），以及 2026 財年的每股收益預期為（$1.61）。</p>
</div><p>A number of other equities analysts have also weighed in on CNTA. Wall Street Zen raised Centessa Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an &#34;overweight&#34; rating and a $35.00 price target on the stock. Chardan Capital reissued a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $33.11.</p>
<div class="lb-trans"><p>其他一些股票分析師也對 CNTA 發表了看法。華爾街 Zen 在 10 月 27 日星期一的研究報告中將 Centessa Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。Stephens 在 10 月 28 日星期二的報告中開始覆蓋 Centessa Pharmaceuticals。他們對該股票設定了 “超配” 評級和 $35.00 的目標價。Chardan Capital 在 8 月 12 日星期二的報告中重申了 “買入” 評級，並對 Centessa Pharmaceuticals 的股票設定了 $30.00 的目標價。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了 Centessa Pharmaceuticals 股票的 “賣出（d-）” 評級。最後，Truist Financial 在 11 月 5 日星期三的報告中對 Centessa Pharmaceuticals 股票設定了 $30.00 的目標價。一位股票研究分析師對該股票給予了強力買入評級，十位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 $33.11。</p>
</div><p><strong>Check Out Our Latest Analysis on CNTA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 CNTA 的最新分析</strong></p>
</div><h2>Centessa Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 價格表現</h2>
</div><p>CNTA stock opened at $27.61 on Monday. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The firm has a market capitalization of $3.70 billion, a PE ratio of -15.09 and a beta of 1.56. The business has a 50 day simple moving average of $23.17 and a 200-day simple moving average of $17.56.</p>
<div class="lb-trans"><p>CNTA 股票在星期一開盤價為 $27.61。Centessa Pharmaceuticals 的一年最低價為 $9.60，一年最高價為 $27.72。該公司的債務與股本比率為 0.36，流動比率為 10.56，速動比率為 10.57。該公司的市值為 37 億美元，市盈率為 -15.09，貝塔值為 1.56。該公司的 50 日簡單移動平均為 $23.17，200 日簡單移動平均為 $17.56。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02).</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals (NASDAQ:CNTA - 獲取免費報告) 最近在 11 月 5 日星期三發佈了季度財報。該公司報告的每股收益為（$0.41），低於分析師的共識預期（$0.39）$0.02。</p>
</div><h2>Insider Activity at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 內部活動</h2>
</div><p>In related news, insider Mario Alberto Accardi sold 8,000 shares of the business's stock in a transaction on Monday, October 27th. The stock was sold at an average price of $25.00, for a total value of $200,000.00. Following the sale, the insider owned 194,394 shares in the company, valued at approximately $4,859,850. The trade was a 3.95% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the firm's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company's stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 179,964 shares of company stock worth $4,106,481. Insiders own 7.09% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Mario Alberto Accardi 在 10 月 27 日星期一以每股平均價格 $25.00 出售了 8,000 股該公司的股票，總價值為 $200,000.00。出售後，該內部人士在公司中持有 194,394 股，價值約為 $4,859,850。這筆交易使其持股減少了 3.95%。該交易已在證券交易委員會的備案中披露，可以通過此鏈接訪問。此外，首席技術官 Tia L. Bush 在 11 月 12 日星期三以每股平均價格 $26.00 出售了 40,000 股該公司的股票，總價值為 $1,040,000.00。交易後，首席技術官持有 121,503 股公司股票，價值 $3,159,078。這筆交易代表其持股減少了 24.77%。該銷售的 SEC 備案提供了更多信息。在上個季度，內部人士出售了價值 $4,106,481 的 179,964 股公司股票。內部人士持有公司股票的比例為 7.09%。</p>
</div><h2>Institutional Trading of Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的機構交易</h2>
</div><p>Several hedge funds have recently made changes to their positions in CNTA. Avoro Capital Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company's stock valued at $262,096,000 after purchasing an additional 5,808,080 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 35.8% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company's stock worth $99,999,000 after buying an additional 1,834,973 shares in the last quarter. Federated Hermes Inc. purchased a new position in Centessa Pharmaceuticals in the 3rd quarter valued at approximately $42,429,000. Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the second quarter worth $16,052,000. Finally, Commodore Capital LP increased its position in shares of Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company's stock worth $43,340,000 after acquiring an additional 930,711 shares during the period. Institutional investors and hedge funds own 82.01% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金最近對 CNTA 的持倉進行了調整。Avoro Capital Advisors LLC 在第三季度將其在 Centessa Pharmaceuticals 的股份增加了 116.2%。Avoro Capital Advisors LLC 現在擁有 10,808,080 股該公司的股票，價值 $262,096,000，此前在此期間又購買了 5,808,080 股。Adage Capital Partners GP L.L.C. 在第一季度將其在 Centessa Pharmaceuticals 的持股增加了 35.8%。Adage Capital Partners GP L.L.C. 現在擁有 6,954,000 股該公司的股票，價值 $99,999,000，此前在上個季度又購買了 1,834,973 股。Federated Hermes Inc. 在第三季度購買了 Centessa Pharmaceuticals 的新頭寸，價值約為 $42,429,000。Balyasny Asset Management L.P. 在第二季度獲得了 Centessa Pharmaceuticals 的新頭寸，價值 $16,052,000。最後，Commodore Capital LP 在第二季度將其在 Centessa Pharmaceuticals 的持倉增加了 39.3%。Commodore Capital LP 現在擁有 3,298,289 股該公司的股票，價值 $43,340,000，此前在此期間又購買了 930,711 股。機構投資者和對沖基金持有公司股票的比例為 82.01%。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於為患者發現、開發和提供藥物。其產品管線包括 SerpinPC，一種用於治療 A 型和 B 型血友病的活化蛋白 C 抑制劑；以及 ORX750，一種用於治療嗜睡症和其他睡眠障礙的口服 OX2R 激動劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Centessa Pharmaceuticals</li>
<li>內部人士出售解釋：它能否影響你的投資選擇？</li>
<li>4 只寒冷天氣股票，適合冬季消費熱潮</li>
<li>深入瞭解買賣差價</li>
<li>迪士尼股票下跌——收益能否為 YouTube TV 和解鋪平道路？</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>Meta 的痛苦可能是你的機會：這是一個罕見的買入窗口嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Centessa Pharmaceuticals 並不在名單上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lifesci Capital 對 CNTA 的收益發布了樂觀的預測